drugset / Trial / NCT07298005
Sonlicromanol in Post-COVID
Phase 2
Recruiting
80 enrolled
Michele van Vugt
Khondrion BV · collabZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).
Timeline
- Start
- 2026-04
- Primary completion
- 2027-02
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sonlicromanol | Small molecule | 90 mg | — |